Working group:
Murine-Lymphoma
Supervisor: PD Dr. Alexander Egle
CLL is a tumor that originates from an outgrowth of immune cells in the body. Similar to normal immune cells, CLL cells are part of a complex relationship composed of other immune cells and tissues components, which is of high importance for the development and progression of the disease. The study of this interplay in patient derived cancer cells has technical limitations as it is not possible to design in vitro experiments and cell culture models that are able to simulate its full complexity. Therefore, in addition to the analysis of human CLL samples, the group develops mouse models to study lymphoma development in vivo. These murine models are used to analyze the disease in its natural surrounding including all possible interaction partners, thus resembling the complexity of the human disease in an appropriate way.
The transplantation model allows to test pharmacological substances and to analyze potential survival benefits:
+ Splenocytes of a transgenic mouse which has developed a CLL-like disease are withdrawn and injected into a healthy, non-transgenic mouse. In this transplanted mouse, a very aggressive leukemia develops, which fully resembles the disease originated in the donor mouse, but has a tumor onset of a few months only. This rapid tumor development makes it possible to test and to analyze pharmacological substances and study whether a certain therapy is able to defeat CLL in the living organisms or at least delay disease progression.
2018
Gold medal for scientific publications, Science Award PMU Salzburg, 2018
Priv. Doz. Dr. Alexander Egle
Research Group: Egle
2017
Platin medal for scientific publications, Scientific Award PMU Salzburg, 2017
Priv. Doz. Dr. Alexander Egle
Research Group: Egle
2016
Researcher of the Year 2016
Priv. Doz. Dr. Alexander Egle
Research Group: Egle
Platin medal for scientific publications, Scientific Award PMU Salzburg, 2016
Priv. Doz. Dr. Alexander Egle
Research Group: Egle
2015
Platin medal for scientific publications, Scientific Award PMU Salzburg, 2015
Priv. Doz. Dr. Alexander Egle
Research Group: Egle
2014
Platin medal for scientific publications, Scientific Award PMU Salzburg, 2014
Priv. Doz. Dr. Alexander Egle
Research Group: Egle
2013
Silver medal for scientific publications, Science Award PMU Salzburg, 2013
Priv. Doz. Dr. Alexander Egle
Research Group: Egle
Best Talk Award-ICA Symposium, Paris Lodron Universität Salzburg, 2013
Eveline Sifft
Research Group: Egle
Best Abstract Award-ÖGHO Spring meeting, 2013
Dr. Daniela Asslaber
Research Group: Egle
2012
Gold medal for scientific publications, Science Award PMU Salzburg, 2012
Dr. Alexander Egle
Research Group: Egle
Silver medal for scientific publications, Science Award PMU Salzburg, 2012
Dr. Josefina Piñón Hofbauer
Research Group: Egle
OeGHO Young Investigator Award 2012
Dr. Daniela Asslaber/Eva Grössinger
Research Group: Egle
2011
Gold medal for scientific publications, Scientific Award PMU Salzburg, 2011
Priv. Doz. Dr. Alexander Egle
Research Group: Egle
Gold medal for scientific publications, Scientific Award PMU Salzburg, 2011
Dr. Josefina Pinon Hofbauer
Research Group: Egle
Outstanding basic research, Sanofi Award, 2011
Dr. Josefina Pinon Hofbauer
Research Group: Egle
2010
Outstanding basic research, Sanofi Aventis Award, 2010.
Dr. Daniela Asslaber
Research Group: Egle
Gold medal for scientific publications, Scientific Award PMU Salzburg, 2010
Priv. Doz. OA Dr. Alexander Egle
Research Group: Egle
Wilhelm Türk Award, Annual Meeting DGHO, ÖGHO, SGH in Berlin, 2010.
Dr. Daniela Asslaber
Research Group: Egle
2009
ÖGHO Spring meeting in Salzburg, 2009.
Priv. Doz. OA Dr. Alexander Egle
Research Group: Egle
2019
Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
Magnes, T, Melchardt, T, Hufnagl, C, Weiss, L, Mittermair, C, Neureiter, D, Klieser, E, Rinnerthaler, G, Roesch, S, Gaggl, A, Greil, R, Egle, A.
Pharmacogenomics J. 2019.
2018
Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters.
Schlick, K, Magnes, T, Ratzinger, L, Jaud, B, Weiss, L, Melchardt, T, Greil, R, Egle, A.
PLoS One. 2018, 13(11): e0206688.
View this publication in the PUBMED database
Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer : A retrospective analysis.
Asamer, E, Szkandera, J, Gibiser, P, Lembeck, AL, Stojakovic, T, Kornprat, P, Lackner, C, Winder, T, Schlick, K, Stoger, H, Gerger, A, Pichler, M, Stotz, M.
WIEN KLIN WOCHENSCHR. 2018, 130(19-20): 569-574.
View this publication in the PUBMED database
Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development.
Zaborsky, N, Gassner, FJ, Höpner, JP, Schubert, M, Hebenstreit, D, Stark, R, Asslaber, D, Steiner, M, Geisberger, R, Greil, R, Egle, A.
Leukemia. 2018.
View this publication in the PUBMED database
Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Egle, A, Steurer, M, Melchardt, T, Weiss, L, Gassner, FJ, Zaborsky, N, Geisberger, R, Catakovic, K, Hartmann, TN, Pleyer, L, Voskova, D, Thaler, J, Lang, A, Girschikofsky, M, Petzer, A, Greil, R.
Ann Hematol. 2018.
View this publication in the PUBMED database
Remission maintenance treatment options in chronic lymphocytic leukemia.
Egle, A, Pleyer, L, Melchardt, T, Hartmann, TN, Greil, R.
Cancer Treat Rev. 2018, 70:5-66.
View this publication in the PUBMED database
Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma.
Leisch, M, Egle, A, Greil, R.
Future Oncol. 2018.
View this publication in the PUBMED database
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Egle, A, Steurer, M, Melchardt, T, Weiss, L, Gassner, FJ, Zaborsky, N, Geisberger, R, Catakovic, K, Hartman, TN, Pleyer, L, Voskova, D, Thaler, J, Lang, A, Girschikofsky, M, Petzer, A, Greil, R.
Ann Hematol. 2018.
View this publication in the PUBMED database
Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia.
Janovska, P, Verner, J, Kohoutek, J, Bryjova, L, Gregorova, M, Dzimkova, M, Skabrahova, H, Radaszkiewicz, T, Ovesna, P, Blanarova, OV, Nemcova, T, Hoferova, Z, Vasickova, K, Smyckova, L, Egle, A, Pavlova, S, Poppova, L, Plevova, K, Pospisilova, S, Bryja, V.
Blood. 2018, 131(11):1206-1218.
View this publication in the PUBMED database
DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer.
Gampenrieder, SP, Rinnerthaler, G, Hackl, H, Pulverer, W, Weinhaeusel, A, Ilic, S, Hufnagl, C, Hauser-Kronberger, C, Egle, A, Risch, A, Greil, R.
THERANOSTICS. 2018, 8(8): 2278-2288.
Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.
Melchardt, T, Magnes, T, Hufnagl, C, Thorner, AR, Ducar, M, Neureiter, D, Tränkenschuh, W, Klieser, E, Gaggl, A, Rösch, S, Rasp, G, Hartmann, TN, Pleyer, L, Rinnerthaler, G, Weiss, L, Greil, R, Egle, A.
Eur J Cancer. 2018, 93:69-78.
View this publication in the PUBMED database
Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia.
Huemer, F, Weiss, L, Faber, V, Neureiter, D, Egle, A, Geissler, K, Voskova, D, Zebisch, A, Burgstaller, S, Pichler, A, Stauder, R, Sperr, W, Lang, A, Pfeilstöcker, M, Machherndl-Spandl, S, Stampfl, M, Greil, R, Pleyer, L.
Wien Klin Wochenschr. 2018.
View this publication in the PUBMED database
Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.
Gutjahr, JC, Szenes, E, Tschech, L, Asslaber, D, Schlederer, M, Roos, S, Yu, X, Girbl, T, Sternberg, C, Egle, A, Aberger, F, Alon, R, Kenner, L, Greil, R, Orian-Rousseau, V, Hartmann, TN.
Blood. 2018.
2017
Update on squamous cell carcinoma of the head and neck: ASCO annual meeting 2017.
Magnes, T, Egle, A, Greil, R, Melchardt, T.
Memo. 2017, 10(4):220-223.
View this publication in the PUBMED database
Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine – A retrospective single center experience.
Leisch, M, Weiss, L, Lindlbauer, N, Jungbauer, C, Egle, A, Rohde, E, Greil, R, Grabmer, C, Pleyer, L.
Leuk Res. 2017, 59:12-19.
View this publication in the PUBMED database
Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy.
Magnes, T, Melchardt, T, Weiss, L, Mittermair, C, Neureiter, D, Klieser, E, Gampenrieder, S, Moser, G, Gaggl, A, Greil, R, Egle, A.
PLoS One. 2017, 12(7):e0180995.
View this publication in the PUBMED database
The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
Magnes, T, Melchardt, T, Hufnagl, C, Weiss, L, Mittermair, C, Neureiter, D, Klieser, E, Rinnerthaler, G, Roesch, S, Gaggl, A, Greil, R, Egle, A.
Pharmacogenomics J. 2017.
View this publication in the PUBMED database
Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
Kazianka, L, Drucker, C, Skrabs, C, Thomas, W, Melchardt, T, Struve, S, Bergmann, M, Staber, PB, Porpaczy, E, Einberger, C, Heinz, M, Hauswirth, A, Raderer, M, Pabinger, I, Thalhammer, R, Egle, A, Wendtner, CM, Follows, G, Hoermann, G, Quehenberger, P, Jilma, B, Jaeger, U.
Leukemia. 2017, 31(5):1117-1122.
View this publication in the PUBMED database
Milestones in Chronic Lymphocytic Leukemia: An exciting decade of progress-10th anniversary of memo.
Egle, A.
Memo. 2017, 10(1):8-12.
View this publication in the PUBMED database
Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial.
Weiss, L, Melchardt, T, Egle, A, Hopfinger, G, Hackl, H, Greil, R, Barth, J, Rummel, M.
Ann Hematol. 2017.
View this publication in the PUBMED database
A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.
Kiesewetter, B, Willenbacher, E, Willenbacher, W, Egle, A, Neumeister, P, Voskova, D, Mayerhoefer, ME, Simonitsch-Klupp, I, Melchardt, T, Greil, R, Raderer, M.
Blood. 2017, 129(3):383-385
2016
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
Greil, R, ObrtlÃková, P, Smolej, L, Kozák, T, Steurer, M, Andel, J, Burgstaller, S, MikuÅ¡ková, E, Gercheva, L, Nösslinger, T, PapajÃk, T, Ladická, M, Girschikofsky, M, HrubiÅ¡ko, M, Jäger, U, Fridrik, M, Pecherstorfer, M, Králiková, E, Burcoveanu, C, Spasov, E, Petzer, A, Mihaylov, G, Raynov, J, Oexle, H, Zabernigg, A, Flochová, E, Palášthy, S, StehlÃková, O, Doubek, M, Altenhofer, P, Pleyer, L, Melchardt, T, Klingler, A, Mayer, J, Egle, A.
Lancet Haematol. 2016, 3(7): e317-e329.
View this publication in the PUBMED database
Bcl-2 proteins in development, health, and disease of the hematopoietic system.
Kollek, M, Müller, A, Egle, A, Erlacher, M.
FEBS J. 2016, 283(15): 2779-2810.
View this publication in the PUBMED database
Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones.
Melchardt, T, Hufnagl, C, Weinstock, DM, Kopp, N, Neureiter, D, Tränkenschuh, W, Hackl, H, Weiss, L, Rinnerthaler, G, Hartmann, TN, Greil, R, Weigert, O, Egle, A.
Oncotarget. 2016, xx:
View this publication in the PUBMED database
NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.
Prochazka, KT, Melchardt, T, Posch, F, Schlick, K, Deutsch, A, Beham-Schmid, C, Weiss, L, Gary, T, Neureiter, D, Klieser, E, Greil, R, Neumeister, P, Egle, A, Pichler, M.
Br J Cancer. 2016, xx:
View this publication in the PUBMED database
Fluorouracil and Dihydropyrimidine Dehydrogenase Genotyping.
Magnes, T, Melchardt, T, Weiss, L, Hufnagl, C, Greil, R, Egle, A.
J Clin Oncol. 2016, 34(20): 2433-2434.
View this publication in the PUBMED database
Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.
Huemer, F, Dejaco, M, Grabmer, C, Melchardt, T, Neureiter, D, Mayer, G, Egle, A, Greil, R, Weiss, L.
Wien Klin Wochenschr. 2016,
Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?.
Zaborsky, N, Gassner, FJ, Asslaber, D, Reinthaler, P, Denk, U, Flenady, S, Hofbauer, JP, Danner, B, Rebhandl, S, Harrer, A, Geisberger, R, Greil, R, Egle, A.
Oncotarget. 2016,
An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide?+?dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM).
Kollek, M, Müller, A, Egle, A, Erlacher, M.
FEBS J. 2016, 283(15):2779-2810
Developing a cancer immunogene therapy approach for Epidermolysis bullosa-associated squamous cell carcinoma.
Melchardt, T, Hufnagl, C, Weinstock, DM, Kopp, N, Neureiter, D, Tränkenschuh, W, Hackl, H, Weiss, L, Rinnerthaler, G, Hartmann, TN, Greil, R, Weigert, O, Egle, A.
Oncotarget. 2016,
CRISPR/Cas9-mediated gene repair in the COL7A1 gene.
Prochazka, KT, Melchardt, T, Posch, F, Schlick, K, Deutsch, A, Beham-Schmid, C, Weiss, L, Gary, T, Neureiter, D, Klieser, E, Greil, R, Neumeister, P, Egle, A, Pichler, M.
Br J Cancer. 2016,
Bcl-2 proteins in development, health, and disease of the hematopoietic system.
Kollek, M, Müller, A, Egle, A, Erlacher, M.
FEBS J. 2016, 283(15):2779-2810
View this publication in the PUBMED database
CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells.
Zaborsky, N, Gassner, FJ, Asslaber, D, Reinthaler, P, Denk, U, Flenady, S, Hofbauer, JP, Danner, B, Rebhandl, S, Harrer, A, Geisberger, R, Greil, R, Egle, A.
Oncotarget. 2016,
View this publication in the PUBMED database
Fluorouracil and Dihydropyrimidine Dehydrogenase Genotyping.
Magnes, T, Melchardt, T, Weiss, L, Hufnagl, C, Greil, R, Egle, A.
J Clin Oncol. 2016, 34(20):2433-2434
View this publication in the PUBMED database
Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo.
Hanna, BS, McClanahan, F, Yazdanparast, H, Zaborsky, N, Kalter, V, Rößner, PM, Benner, A, Dürr, C, Egle, A, Gribben, JG, Lichter, P, Seiffert, M.
Leukemia. 2016, 30(3): 570-579.
View this publication in the PUBMED database
The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma.
Troppan, KT, Melchardt, T, Wenzl, K, Schlick, K, Deutsch, A, Bullock, MD, Reitz, D, Beham-Schmid, C, Weiss, L, Neureiter, D, Tränkenschuh, W, Greil, R, Neumeister, P, Egle, A, Pichler, M.
J Clin Pathol. 2016, 69(4):326-330.
View this publication in the PUBMED database
ILK Induction in Lymphoid Organs by a TNFα-NF-κB-Regulated Pathway Promotes the Development of Chronic Lymphocytic Leukemia.
Krenn, PW, Hofbauer, SW, Pucher, S, Hutterer, E, Hinterseer, E, Denk, U, Asslaber, D, Ganghammer, S, Sternberg, C, Neureiter, D, Aberger, F, Wickström, SA, Egle, A, Greil, R, Hartmann, TN.
Cancer Res. 2016, 76(8):2186-2196.
View this publication in the PUBMED database
The AKT1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells.
Hofbauer, SW, Krenn, PW, Piñόn Hofbauer, J, Pucher, S, Asslaber, D, Egle, A, Hartmann, TN, Greil, R.
Br J Haematol. 2016, 172(5): 815-819.
View this publication in the PUBMED database
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.
“Rawstron, AC, Fazi, C, Agathangelidis, A, Villamor, N, Letestu, R, Nomdedeu, J, Palacio, C, Stehlikova, O, Kreuzer, KA, Liptrot, S, O””Brien, D, de Tute, RM, Marinov, I, Hauwel, M, Spacek, M, Dobber, J, Kater, AP, Gambell, P, Soosapilla, A, Lozanski, G, Brachtl, G, Lin, K, Boysen, J, Hanson, C, Jorgensen, JL, Stetler-Stevenson, M, Yuan, C, Broome, HE, Rassenti, L, Craig, F, Delgado, J, Moreno, C, Bosch, F, Egle, A, Doubek, M, Pospisilova, S, Mulligan, S, Westerman, D, Sanders, CM, Emerson, R, Robins, HS, Kirsch, I, Shanafelt, T, Pettitt, A.Kipps, TJ, Wierda, WG, Cymbalista, F, Hallek, M, Hillmen, P, Montserrat, E, Ghia, P.”
Leukemia. 2016, 30(4):929-936.
View this publication in the PUBMED database
Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones.
Melchardt, T, Hufnagl, C, Weinstock, DM, Kopp, N, Neureiter, D, Tränkenschuh, W, Hackl, H, Weiss, L, Rinnerthaler, G, Hartmann, TN, Greil, R, Weigert, O, Egle, A.
Oncotarget. 2016.
“The complexity of the disease can be mimicked in the murine model. In this system we are analyzing the effect of novel therapy concepts and the communication of leukemic cells with the immune system.”
Team
Priv. Doz. OA Dr. Alexander Egle
(Supervisor)
Dr. Daniela Asslaber
(Post-Doc)
Jennifer Forster, MSc
(PhD Student)
Do you have a request or any questions?
Feel free to contact us – we will get back back to you as soon as possible.